Main Uses of Mesavancol

Mesavancol is a medication primarily used for the management of ulcerative colitis, a chronic inflammatory bowel disease (IBD). It belongs to a group of medicines known as aminosalicylates, which work to reduce inflammation within the digestive tract.

Treatment of Active Ulcerative Colitis

In its active phase, ulcerative colitis causes the lining of the large intestine (colon) and rectum to become inflamed, leading to small ulcers or sores. Mesavancol is used to treat mild to moderate flare-ups by acting locally on the inflamed tissue. The goal of treatment during this phase is to achieve remission, which is the resolution of clinical symptoms and the healing of the intestinal lining.

Maintenance of Remission

Beyond treating active symptoms, Mesavancol is used as a long-term maintenance therapy. Once the inflammation is under control, continued use of the medication helps to prevent the symptoms from returning. By maintaining a state of remission, the medication helps reduce the frequency and severity of future flare-ups.

Benefits and Mechanism of Action

Targeted Anti-Inflammatory Effect

Mesavancol utilizes a specific delivery system designed to release the active ingredient, mesalazine, throughout the entire length of the colon. This ensures that the medication reaches the areas most affected by ulcerative colitis. Unlike systemic anti-inflammatories, it works topically on the bowel wall to minimize the production of substances that trigger inflammation.

Symptom Management

By controlling the underlying inflammation, Mesavancol helps alleviate the characteristic symptoms associated with ulcerative colitis, which may include:

• Frequent bowel movements or urgency.
• Abdominal pain and cramping.
• Rectal bleeding associated with inflammation of the colon lining.

Mucosal Healing

Effective treatment with Mesavancol can lead to mucosal healing. This refers to the physical repair of the intestinal lining as seen during medical examinations. Achieving mucosal healing is a key objective in the long-term management of inflammatory bowel disease, as it is often associated with better clinical outcomes and a reduced risk of complications.

Who Can and Cannot Use Mesavancol?

This section outlines the official population eligibility and non-eligibility rules for Mesavancol (Mesalazine), strictly based on governmental regulatory labeling.

---

Populations for Whom Use is Established

Mesavancol is authorized for use in adults and for specific formulations in pediatric patients 5 years of age and older. Use in children younger than 5 years is typically not established by regulatory bodies.

Absolute Contraindications

Mesavancol is contraindicated and must not be used by patients with a known or suspected hypersensitivity (allergy) to salicylates (such as aspirin), aminosalicylates (mesalamine), or any inactive ingredient in the tablet formulation.

Conditional Use and Restrictions

Use requires caution and mandatory monitoring for individuals with pre-existing renal impairment or a history of liver disease. Renal function must be evaluated prior to starting therapy and periodically thereafter. The medicine should be avoided in patients with a severe upper gastrointestinal tract obstruction, such as pyloric stenosis, due to its delayed-release design.

Pregnancy and Lactation

Use during pregnancy is conditional and should occur only if the potential benefit justifies the potential risk to the fetus, as there are insufficient human studies. Caution must be exercised when administering Mesavancol to a nursing woman.

The official regulatory interaction profile for Mesalazine is strictly defined by documented effects on metabolic enzymes, potential for additive organ toxicity, and specific requirements for administration.

High-Risk Combinations

Co-administration with the purine analogues, specifically Azathioprine, 6-Mercaptopurine, or Thioguanine, is associated with a high-risk interaction classified by regulatory bodies. This interaction stems from Mesalazine's documented inhibition of the thiopurine methyltransferase (TPMT) enzyme, leading to a critical increase in the exposure of the toxic metabolites from the purine analogue. The official outcome of this drug–drug interaction is an elevated risk of severe myelosuppression (blood disorders and bone marrow failure).

Pharmacodynamic and Organ Risk

An additive organ toxicity risk is documented when Mesalazine is co-administered with other nephrotoxic agents, including Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). This interaction may result in an increased risk of renal adverse reactions, with a specific caution noted for patients who have pre-existing renal impairment. Furthermore, regulatory information notes a possible potentiation of the anticoagulant effect when Mesalazine is used concurrently with Coumarin-type anticoagulants.

Procedural Constraints

The administration of the delayed-release tablet is officially constrained by a required condition to be taken with food, which is necessary for achieving the product's intended absorption kinetics as described in labeling. Separately, Mesalazine is documented to interfere with laboratory testing, specifically causing spuriously elevated urinary Normetanephrine results when tested using specific detection methods.

Mesavancol's mechanism of action is a localized and multi-target anti-inflammatory process exerted directly on the mucosal lining of the lower digestive tract. Its efficacy is contingent upon the drug being released in high concentration at the affected tissue. .

Modulating the Production of Inflammatory Mediators

This core mechanism involves inhibiting key enzymes, specifically Cyclooxygenase (COX) and Lipoxygenase (LOX), that are responsible for synthesizing pro-inflammatory signaling molecules like prostaglandins and leukotrienes ( LTB4). By suppressing the creation of these signaling chemicals, Mesalazine reduces the activity of the localized inflammatory cascade and reduces the chemical signals responsible for immune cell recruitment (chemotaxis) to the area.

Suppressing Pro-Inflammatory Gene Expression

Mesalazine influences the genetic switches controlling cellular inflammation by inhibiting Nuclear Factor-kappa B ( NF-kappa B) and activating the PPARgamma receptor. This dual action suppresses the genes that produce inflammatory cytokines ( TNF-alpha, IL-1beta) while promoting anti-inflammatory gene output, modulating the local tissue environment's output of inflammatory mediators.

Localized Tissue Protection

The drug functions as a topical antioxidant by scavenging and neutralizing Reactive Oxygen Species (ROS)—unstable free radicals—that cause cellular and tissue damage during inflammation. This action physically protects the mucosal lining from oxidative stress, contributing to reducing the tissue-damaging effects of oxidative stress.

Mesavancol (mesalamine) is administered exclusively via the oral route as a delayed-release tablet. This specific formulation requires the tablets to be swallowed whole and must not be crushed, split, or chewed, which is a crucial administration constraint designed to protect the specialized coating and ensure the active ingredient is delivered to the lower bowel.

The medicine is characterized by a once-daily administration pattern for both the initial and long-term phases of use. The total daily dose is required to be taken with food (a meal) to facilitate the intended drug-release profile. If a dose is missed, it should be taken as soon as it is remembered, unless the time is approaching the next scheduled dose, in which case the missed dose should be entirely skipped.

Dose ranges are based on the treatment goal. For the induction of remission (managing active, mild-to-moderate disease), the standard daily dose ranges from 2.4 g to a maximum of 4.8 g of mesalamine. For the maintenance of remission (long-term use), the standard dose is 2.4 g once daily. Usage in pediatric patients (ages five and older and 24 kg) requires adherence to a weight-based regimen.

Research Evidence / Overview of Studies

Research Focus on Biological Action

Research began by investigating the potential biological actions of the compound. Research evaluated whether the compound affects inflammation in animal models, and preliminary studies collected data on pain scores in human participants. Examinations focused on the time course and duration of changes in symptoms.

---

Clinical Trial Findings

Phase 3 Data Collection

A large-scale, double-blind, placebo-controlled trial (N=1,500) served as the primary investigation into the drug’s use. Key data points included:

• Pain Score Collection: The main outcome measure was the change in VAS (Visual Analogue Scale) pain score over 12 weeks. The trial results documented the collected pain scores (Visual Analogue Scale) between the compound group and the placebo group at several intervals.
• Functional Metrics: A secondary outcome involved the assessment of patients' self-reported daily activity levels. Research examined the data related to the combined action of the drug components on these functional metrics.
• Scope of Research: Studies have explored its use across diverse pain types, including neuropathic and inflammatory pain.

Safety and Tolerability Profile

Initial evaluations examined the drug’s tolerability in adult participants over the 12-week study duration.

• Common Side Effects: The most frequently reported adverse events included mild nausea, headache, and transient gastrointestinal upset. The observed side effects were documented in trials.
• Liver Function: Some trials included monitoring liver function biomarkers. Differences in liver enzyme levels between treatment and placebo groups were documented.
• Long-term Assessment: Studies on the compound included assessment of use over extended durations (up to 52 weeks) to document tolerability and potential adverse events over a longer period.

---

Special Population Research

Investigating Timing of Administration

The timing of administration, including early use, has been a subject of research. A separate study examined effects when the compound was administered within 48 hours of symptom onset. Research compared data on the duration of flare-ups in participants who received the compound early versus those who received it later in the course of the flare-up.

Studies in Elderly Participants

A small, single-center study specifically assessed the compound’s profile in adults over 65. The study monitored plasma concentrations and tolerability. Adverse events reported in this population were documented during the 8-week observation period.

Common questions about Mesavancol (FAQ)

Q: How quickly is Mesavancol expected to start working for the condition it treats?

A: Official patient information indicates that while the medicine begins working immediately upon administration, an improvement in symptoms may be typically observed around one week after starting treatment. The full observed effects of the medicine in clinical contexts may take a few months to become apparent.

Q: Is it possible for Mesavancol to affect my sleep patterns?

A: Official documentation describes that the drug’s active ingredient can affect the Nervous System, with headache and dizziness being noted effects. However, specific changes to sleep patterns, such as insomnia or drowsiness, are not typically listed as common reported adverse reactions.

Q: What happens if I miss taking a dose of Mesavancol?

A: According to the official administration instructions, a missed dose should be taken as soon as it is remembered. Official administration requirements indicate that if the time is approaching the next scheduled dose, the missed dose is to be skipped.

Q: Is Mesavancol known to interact with common pain relievers like ibuprofen?

A: Regulatory information describes that co-administering Mesalazine with other agents that can affect the kidneys, such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) like ibuprofen, may lead to an increased risk of renal (kidney) adverse reactions. This documented interaction often necessitates careful monitoring by a healthcare professional.

Q: Is Mesavancol a brand name, and what is the generic equivalent?

A: Mesavancol is a brand name for the active ingredient Mesalazine. Mesalazine is also known as mesalamine or 5-aminosalicylic acid (5-ASA), which is the generic name for the compound.

Q: Does Mesavancol need to be stored in a special way, like refrigeration?

A: Official guidelines instruct that Mesavancol should be stored at controlled room temperature, generally below 25 C (77 F). It must also be protected from light and moisture. Refrigeration is not required or instructed for the product.

Q: Can Mesavancol affect my mood or cause changes in behavior?

A: While rare adverse reaction reports have included signs related to cognitive disturbances, general behavioral or mood changes are not listed as common or frequent adverse reactions in official safety information. Unusual changes, if experienced, are typically reviewed by a healthcare professional.

Q: What information is available regarding Mesavancol use in elderly patients?

A: Caution is advised for use in older adults, and regulatory documents include the requirement for mandatory monitoring of kidney function in this population. The safety profile of the medicine was assessed specifically in this population.

Q: How is the safety profile of Mesavancol described in official documents?

A: The official safety profile is characterized by Gastrointestinal and Nervous System effects, such as headache, nausea, and abdominal pain, as the most frequent adverse reactions. Serious, though rare, concerns documented include hypersensitivity reactions and organ inflammation affecting the kidney or heart.

Q: Can Mesavancol be used by children, or is it only for adults?

A: Mesavancol is authorized for use in adults and for specific formulations in pediatric patients 5 years of age and older. Regulatory authorities define that the dose for children is determined according to a weight-based regimen.

Q: Does taking Mesavancol affect the results of any routine lab tests?

A: Official prescribing information documents that this medication may interfere with certain laboratory tests. Specifically, it can cause spuriously elevated urinary Normetanephrine results when specific detection methods are used during testing.

Q: Is it necessary to take Mesavancol indefinitely, or is it for a set time?

A: The medicine is officially prescribed for two distinct purposes: the induction of remission (managing active disease) and the maintenance of remission. For the maintenance phase, it is often used for long-term management to help prevent flare-ups of the chronic condition.

Q: What are the signs of a rare but serious side effect that I should be aware of with Mesavancol?

A: Rare but serious adverse reactions documented in official safety information include severe hypersensitivity reactions and organ inflammation, such as Myocarditis (heart inflammation) and Interstitial Nephritis (kidney inflammation). Serious skin reactions (SJS/TEN) have also been reported.

Q: Is it normal to feel slightly nauseous when first starting Mesavancol?

A: Nausea is one of the most frequently reported adverse reactions for Mesalazine, classified as Common in official prescribing information. This finding is consistent with effects described in the product’s official information.

Q: Can I take Mesavancol if I have a history of liver or kidney problems?

A: Regulatory documentation states that Mesavancol is contraindicated (must not be used) in patients with severe liver and/or renal (kidney) impairment. For patients with less severe pre-existing liver or kidney problems, regulatory conditions require caution and mandatory function monitoring.

Q: How long does the effect of one dose of Mesavancol typically last?

A: Mesavancol is formulated as a delayed-release or extended-release tablet designed for a once-daily administration schedule. This formulation ensures the active ingredient is released over time to sustain a therapeutic effect throughout an approximately 24-hour period.

Q: Does Mesavancol interact with birth control pills?

A: Official patient information describes that mesalamine does not affect hormonal contraception. However, if the medication causes vomiting or severe, watery diarrhea, this may interfere with the absorption and effectiveness of oral contraceptive pills.

Q: Where can I find the official prescribing information for Mesavancol?

A: Official prescribing information can be accessed through the websites of national government regulatory bodies. Examples include the U.S. Food and Drug Administration (FDA) DailyMed or the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC).

Q: Is Mesavancol considered an immunosuppressant?

A: Mesavancol’s active ingredient, Mesalazine, is classified as an aminosalicylate drug. It is recognized as a local anti-inflammatory agent due to its targeted action on the bowel lining, and it is not typically classified as a systemic immunosuppressant drug.

Q: What are the general expectations about the benefit a patient might experience with Mesavancol?

A: The medicine's purpose is to deliver a powerful local anti-inflammatory effect directly to the bowel lining. This action is intended to relieve irritation and discomfort associated with the chronic condition and help the damaged tissue begin healing.

Q: Are there any restrictions on driving or operating machinery while taking Mesavancol?

A: Official product information states that the medicine has no or negligible influence on the ability to drive or operate tools and machinery. Individuals are generally advised to be aware of any specific side effects they may experience.

Q: Does the time of day I take Mesavancol matter?

A: Mesavancol is approved for a once-daily dosing schedule and is required to be taken with food (a meal) to ensure proper drug release. There is no specific regulatory requirement that fixes the time of day (morning or evening) for administration.

Q: Are there specific symptoms of the treated condition that Mesavancol is best at managing?

A: The medicine is intended to manage the symptoms of chronic inflammatory conditions by delivering a powerful local anti-inflammatory effect directly to the bowel lining. The primary goal is to relieve irritation and discomfort and reduce the inflammation caused by the disease.

Q: Do studies suggest that Mesavancol loses its effect over time?

A: Official guidance confirms that Mesavancol is commonly prescribed for the long-term maintenance of remission in chronic inflammatory conditions. This indicates that the medicine is expected to maintain its beneficial effect over extended periods of use.

Q: Is Mesavancol ever prescribed for conditions other than its main approved use?

A: Regulatory patient information states that the drug may be prescribed for other uses outside of its main approved condition. However, official drug labels focus exclusively on the approved indication.

Q: Is the main ingredient in Mesavancol naturally occurring or synthetic?

A: The active ingredient, Mesalazine (5-ASA), is classified in official documents as a synthetic small molecule. This means it is manufactured and does not originate from a naturally occurring source.

Q: Does Mesavancol need to be adjusted for individuals with a low body weight?

A: Yes, for the pediatric patient population (ages five and older), regulatory authorities define that the recommended dose is calculated using a weight-based regimen.

Q: Is Mesavancol listed on the World Health Organization's list of essential medicines?

A: Mesalazine, the active ingredient in Mesavancol, is included on the World Health Organization (WHO) Model List of Essential Medicines. This listing signifies its importance in a basic health system.

Q: What is the typical timeframe for a follow-up appointment after starting Mesavancol?

A: Regulatory guidelines suggest that for new treatment, follow-up testing is recommended 14 days after commencement, followed by checks at 4-week intervals. If initial findings are normal, subsequent follow-up tests are typically recommended every three months.

Storage and Disposal of Mesavancol

Official guidelines require mesalamine delayed-release tablets to be stored under controlled conditions to maintain stability.

Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, generally below 25 C (77 F).
Protection	Must be protected from light and moisture.
Packaging	Keep in the original container and out of the sight and reach of children.

Disposal Instructions

Unused or expired Mesavancol must be handled according to strict environmental guidelines. Do not throw away medicines via wastewater or household waste. All unused product and waste material must be disposed of in accordance with local regulations.